Skip to content
AwesomeTechnologyPodcasts
Industry Technology

Top 10

HealthTech, MedTech & Biotechnology podcasts

Digital health, medical technology, healthcare software, biotechnology, diagnostics, and health data.

Sector list

Top 10 HealthTech, MedTech & Biotechnology Podcasts of 2026

Showing 10 of 10

Listen now

Latest in HealthTech, MedTech & Biotechnology

All latest episodes
Talking HealthTech37 min

637 - The Future of Traceability in CSSD: RFID, Compliance, and Global Practices

In this episode of Talking HealthTech, Peter Birch speaks with Violeta Addamo, founder and managing director at WHITECAT, and David Bellamy, vice president for the World Federation of Hospital Sterilisation Services and president of the New South Wales Sterilisation Research and Advisory Council of Australia. Violeta shares how her path into healthtech began in environmental science before moving through dental and surgical sales, eventually leading to the founding of WHITECAT six years ago, built on CareTag, a Danish RFID system for surgical instrument management. David brings his standing as a recognised industry leader in sterilisation through his role representing the WFHSS on the global stage. The conversation explores the challenges and advancements in surgical instrument traceability, the implementation of RFID technology in sterilisation departments, compliance with unique device identification (UDI) requirements, and global practices in healthtech for instrument management The episode also covers how Central Sterile Services Departments (CSSD) manage the cleaning, sterilisation, and tracking of surgical instruments, and the risks that arise when these processes rely on manual systems such as paper logs and barcode scanning. It also looks at how RFID and real-time location systems are being trialled to improve visibility across the instrument lifecycle, reduce search times, and support faster responses to sterility breaches or recalls. Further topics include the regulatory landscape shaping instrument management in Australia and abroad, including requirements set by the Therapeutic Goods Administration and the Australian Council on Healthcare Standards, as well as comparisons with practices in Europe and emerging trials across Asia. The discussion closes with a look at what these advancements mean for the future of surgical safety and hospital efficiency. Key Takeaways 🛠 The importance of surgical instrument traceability for both patient safety and operational efficiency in healthcare settings 📡 The evolution and adoption of RFID technology for real-time tracking of surgical instruments, including the limitations of traditional data matrix approaches 📝 The introduction of UDI requirements in Australia and the implications for compliance and traceability in sterilisation processes 🔄 How digitisation and technology reduce manual effort, errors, and the time required to handle equipment recalls 🌏 A comparison of global approaches to sterilisation and traceability, highlighting differences in technology adoption between Australia, Europe, and the USA Timestamps 00:00 - Introductions and guest backgrounds 02:06 - Real-time location tracking and RFID in surgical instruments 05:03 - Traceability challenges and compliance requirements 09:01 - RFID vs data matrix for instrument-level tracking 10:47 - UDI compliance and future standards 15:40 - Manual vs digital recall management 22:51 - Global perspectives and best practices Check out the episode and full show notes on the Talking HealthTech website. Mentioned in this episode: Join THT+ Solo to connect with other people working in or moving into digital health through members-only events, deeper content and the Talking HealthTech community hub:.

The Healthtech Podcast1 hr 20 min

#464 How to go to market in healthtech - Ross Drynan from We Don’t Consult

Ross Drynan has spent twelve years at the intersection of technology and healthcare, almost all of it in go to market, including building the go to market that took a small dental software company to international market leadership. He now runs We Don't Consult, which despite the name is a consultancy, working with clinicians becoming founders, SaaS companies stuck after their first few percent of market share, and established teams trying to work out AI adoption. The conversation opens on why so many clinical founders fail, and it is not the product. Ross argues most spend years and their own money building something nobody has seen, then find they have never practised explaining it. He makes the case for validating cheaply first, including a defence of vibe coding as a founder's tool rather than an engineering embarrassment. From there it gets less comfortable. Healthcare buyers, unlike buyers in most B2B markets, are not thinking about your problems at all, and Ross has the best piece of feedback he has ever received to prove it. He walks through what he calls the narrow bridge: foundations, codifying your expertise, giving your ideas away for free, selling with a diagnostic rather than a demo, proving value so customers attribute the outcome to you, and leverage. There is also a hopeful stretch near the end about redeploying people rather than replacing them.

BioCentury This Week32 min

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route to NASDAQ. On the latest BioCentury This Week podcast, BioCentury's analysts examine momentum in the biotech IPO market. The team also unpacks fatal toxicities in Novartis' autoimmune CAR-T trials and what they reveal about manufacturing, dosing and immune biology risks across the modality. In Washington, Steve Usdin previews Heidi Overton's FDA Commissioner confirmation hearing and reports on the persistent uncertainty around pharma tariffs ahead of the Sept. 29 deadline. Reach us by sending a text

The Heart of Healthcare37 min

Can AI Finish What The Quality Revolution Started? | Bunkerhill Health CCO Dr. Azita Hamedani

For decades, healthcare's quality movement gave us checklists, forcing functions, and protocols to catch human error before it reached a patient. It worked, to a point. But as medical knowledge and patient complexity keep outpacing what any human system can track, a new question is emerging: can AI pick up where that movement left off? In this episode, in her first interview since stepping into the role, we talk with Dr. Azita Hamedani, the newly appointed Chief Clinical Officer at Bunkerhill Health, an AI company backed by Sequoia and Khosla Ventures. After nearly her entire career in academic medicine, Azita made the leap to a startup chasing a promise she's been thinking about since medical school. We cover: The medical school moment that first pulled her toward patient safety over bench science Why she believes healthcare has hit the ceiling of what checklists and protocols alone can do The three different types of health system leaders who all understand a different piece of the AI puzzle, and why that's a problem What actually happened behind the scenes on one real patient's chart, without a single human triggering it Her take on the Khosla and AMA debate over whether doctors should stay in the loop A personal story from her own cancer diagnosis, and the one question she asked her surgeon that no AI could ever answer About our guest: Azita G. Hamedani, MD, MPH, MBA, is the Chief Clinical Officer at Bunkerhill Health. She joined the company based on the belief that its long-horizon AI agent is the first technology capable of ensuring every patient receives optimal care. She spent 25 years in various leadership roles within large-scale academic health systems. Most recently, she served as President and CEO of UNC Faculty Physicians and Vice Dean for Clinical Affairs at the University of North Carolina School of Medicine. Dr. Hamedani also spent nearly two decades at the University of Wisconsin School of Medicine and Public Health and UW Health, where she founded the Department of Emergency Medicine and chaired it for over a decade, while also leading system initiatives related to quality and innovation. She completed her emergency medicine training at Mass General Brigham, and completed a fellowship in hospital administration at Massachusetts General Hospital.

Beyond Biotech40 min

The best biotech conversations you missed this summer

Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months. We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on outsmarting the liver altogether. We'll meet the founders behind these companies, including Andy Parker of Step Pharma and Gene Mack of Gain Therapeutics , and the unlikely paths that got them there. We'll dig into the science of nonsense mutations with Nerissa Kreher of Alltrna , circular RNA with Lu Gao of Therorna , and a cancer target hiding in human genetics. And we'll close with what these leaders think success actually looks like, years from now. So sit back, and let's revisit some of our favourite moments from the summer. 02:32 Solving the delivery problem 08:39 Founder journeys 15:13 Platform science 24:41 Business, money, and geopolitics 32:28 Looking ahead Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Episode 204: The first PROTAC is here. What comes next in protein degradation? Episode 205: Turning cancer cell dependencies into targeted therapies Episode 208: Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's Episode 209: Why Western pharma is sleeping on China's circular RNA revolution Episode 211: Beyond biology: Nanobiotix's physics-first approach to cancer Episode 213: How Evox Therapeutics is targeting CNS diseases with exosomes Episode 214: Rewriting the rules of genetic medicine with tRNA therapeutics

The Readout LOUD28 min

Definium's new psychedelics data, and a reprieve for international scientists

International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the latest news in the life sciences, on this week's episode of "The Readout LOUD." STAT reporter Jonathan Wosen and Fanta Aw, the executive director of NAFSA: Association of International Educators, join the podcast to discuss a recent court decision around foreign visas for students. We also discuss the Definium's psychedelics data and what it means for that field as a whole. Be sure

Faces of Digital Health47 min

Epic or open platforms? The choice facing European hospitals (Nils Hellrung)

Most interoperability debates focus on exchange formats. In this discussion with Dr Nils Hellrung, medical informatician and CEO Strategy & Operations at vitagroup, Nils focuses on the need for shaping hospital IT with governance and financing. Linking proprietary systems through standards, he says, will always lose meaning, which is why he backs openEHR as a vendor-neutral clinical data core, with FHIR used for exchange. vitagroup in providing the data platform for Catalonia, and just signed a contract with a large hospital group in France. The discussion touches different market approaches to interoperability and challenges of markets such as Germany, where each federal state has its own authority to regulate and implement as they please. Tjasa Zajc and Nils Hellrung talk about what "AI-native" data integration means in practice, why 95% accuracy of AI is not good enough in healthcare, and whether Europe ends up with monolithic US EHRs or open platforms. This episode is supported by vitagroup. GUEST Dr Nils Hellrung — CEO Strategy & Operations, vitagroup; medical informatician; co-author, "Health Information Systems: Architectures and Strategies" Host: Tjaša Zajc WHAT THE CONVERSATION COVERS Why hospital IT architecture reflects governance, trust and financing: three professors, three PACS Billing versus therapy: why German hospital and ambulatory systems don't talk to each other AI in healthcare: the widening gap between what is possible and what happens in practice Why Europe doesn't have to be slower than the US in digital health Data availability as the main barrier to digital health implementation openEHR vs FHIR: clinical data repository vs communication standard FHIR version changes and national profiles: the semantic interoperability problem Is European Health Data Space (EHDS) interoperability achievable, or only for a core data set? Catalonia's single patient record on openEHR: 18 months to go-live and the next step to an open health platform Why Catalonia's single health system makes adoption easier Germany: 16 federal states, 17 data protection authorities, and a 20-year-old electronic patient record (ePA) programme Alliance SIH in France: competitors agreeing on a shared health data layer AI as a translator between clinical data and clinicians AI-native vs AI-enabled software, and why data pipelines must stay deterministic Deskilling risk: clinicians who stop thinking because AI seems to have the answer Epic at Charité, monolithic EHRs vs open platforms, and European digital sovereignty in healthcare Europe's health IT ecosystem in 2036: best, worst and realistic scenarios CHAPTERS 02:30 From textbook to practice: 15 years of health information systems 03:00 Why hospital IT looks the way it does: three professors, three PACS 06:50 Is AI speeding up healthcare? The gap between possible and real 10:39 EHDS and data availability: the biggest barrier to digital health 14:00 openEHR vs FHIR: how health data normalisation works in practice 16:40 Is European interoperability achievable? Apple Podcasts:. LinkedIn: / faces-of-digital-health #openEHR #EHDS #interoperability #digitalhealth #healthdata #FHIR #healthIT #healthcareAI #EuropeanHealthDataSpace #Catalonia #vitagroup #FacesOfDigitalHealth

DeviceTalks Weekly53 min

Ep 304 - J&J MedTech's Polyphonic Lead Explains Why Surgical Intelligence Is the Next Big Shift in the OR

In this episode, MassDevice Editor Chris Newmarker interviews Shan Jegatheeswaran, Global President, Polyphonic, Johnson & Johnson MedTech, about what’s to come after the transformation brought to the operating room by digital surgery and robotics. Jegatheeswaran reports that a new wave of surgical intelligence could take that transformation much further by connecting devices, data, AI and clinicians across the entire perioperative pathway. Jegatheeswaran explains why the biggest challenges may no longer be technological. Interoperability, economic incentives, governance, change management and trust all have to evolve alongside AI and connected medical devices. We’ll open the episode with this week’s Newmarker’s Newsmakers – Petal Surgical, Boston Scientific, Medtronic, Zimmer Biomet and Abbott. Enjoy the show? Want access to the complete DeviceTalks Podcast Network (DTPN)?

The Med Device Cyber Podcast39 min

Can We Detect Skin Cancer Without a Biopsy? with Stefan Mazy | Ep 84

What if the biggest problem in skin cancer diagnosis is not finding suspicious lesions, but what happens after we find them? Stefan Mazy joins Christian Espinosa to discuss the personal experience that led him to explore a different approach to skin cancer testing after his mother underwent extensive surgery for an aggressive basal cell carcinoma. Stefan explains how his team is developing a microneedle patch designed to collect cellular tissue without a traditional surgical biopsy, and why he believes the current diagnostic pathway is struggling to scale as skin cancer awareness and testing increase. The conversation also explores the role of AI in identifying suspicious lesions, the trade-off between sensitivity and specificity, and why detecting more abnormalities could increase pressure on an already strained clinical pathway. Christian and Stefan also discuss cybersecurity in medical technology, manufacturing risks, brain-computer interfaces and why connected devices require founders to think beyond the device itself. In This Episode: 03:33 Stefan’s mother’s skin cancer diagnosis 08:14 Why he began searching for an alternative to biopsy 10:08 The scale of unnecessary skin biopsies 12:37 How the microneedle patch works 15:13 Why uncertainty creates a diagnostic bottleneck 23:44 Can AI reliably identify skin cancer?